Tim3 and Mycobacterium tuberculosis
Tim3 and Mycobacterium tuberculosis
批准号:
8652944
负责人:
SAMUEL M BEHAR
金额:
$52.91万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-01 至 2016-06-30
关键词:
4-ethoxymethylene-2-phenyl-2-oxazoline-5-oneAbbreviationsAcquired Immunodeficiency SyndromeAcuteAddressAffectAntigen-Presenting CellsAntimicrobial EffectApoptosisBacteriaBindingCD8B1 geneCaspase-1Cell LineCell surfaceCellsChimeric ProteinsChronicColony-forming unitsDataDendritic CellsDiseaseEquilibriumFunctional disorderGalactose Binding LectinGrowthHost resistanceHumanImmuneImmune responseImmune systemImmunityImmunoglobulinsIn VitroInfectionInflammationInterferonsInterleukin-1Interleukin-1 betaInterleukin-12Interleukin-18IntravenousKnock-outLeadLigandsLungMajor Histocompatibility ComplexMediatingMediator of activation proteinMolecularMucinsMusMycobacterium tuberculosisMyeloid CellsNatural ImmunityNitric OxideNitrogenOutcomeOxidasesOxygenPathway interactionsPeritonealPhagocytesPhysiologicalPlayProductionProtein FamilyPulmonary TuberculosisRecruitment ActivityReportingResearchResearch ProposalsRoleSignal TransductionStaining methodStainsT-LymphocyteTNF geneTestingTissuesToll-like receptorsTransgenic OrganismsTuberculosisTumor Necrosis Factor-alphaVirulentVirus Diseasesadaptive immunityantimicrobialbactericidecytokinedesignexhaustionfunctional statusglobal healthhuman NOS2A proteinimmunopathologyin vivoin vivo Modelkillingslymph nodesmacrophagemembermicrobialmycobacterialnovelpathogenprematurepublic health relevanceresearch studyresponsetuberculosis immunitytuberculosis treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Immunity to microbial pathogens involves numerous checks and balances that are regulated by multiple pathways. This application addresses the novel and potentially critical role that Tim3, a member of the T cell Immunoglobulin and Mucin domain family of proteins, plays in the defense against tuberculosis. Tim3 is emerging as an important regulator of both adaptive and innate immunity, and is conserved between humans and mice. However, the role of Tim3 in modulating immunity to bacterial pathogens has not been examined. While signaling via Tim3 on TH1 cells has been purported to deliver a negative signal that could reduce unintended tissue inflammation, the consequence of Tim3 binding to its ligand on participating antigen-presenting cells is unclear. We have discovered that Tim3 binding to its ligand, Galectin-9 (Gal9) stimulates antibactericidal activity in innate cells both in vivo and in vitro. Tim3 engagement of Gal9 expressed by Mtb infected macrophages induces caspase-1 dependent IL-12 secretion and restricts intracellular bacterial replication. We also find that Tim3-expressing CD4+ and CD8+ T cells accumulate in the lungs of mice infected with virulent M. tuberculosis (Mtb). If, as has been reported for human T cells during chronic viral infection, Tim3-signaling leads to T cell dysfunction and apoptosis, we hypothesize that interactions between Tim3+ T cells in the lung and Gal9 expressing macrophages leads to T cell exhaustion and impairs anti-mycobacterial immunity. Thus, it appears that Tim3 and Gal9 are central players in a bidirectional regulatory circuit that modulates antimicrobial TH1 responses. In the case of acute infection, this circuit could be an important mechanism that limits tissue damage and immunopathology from an overly exuberant immune response, while simultaneously activating innate immunity against microbial pathogens. On the other hand, such a mechanism may be detrimental during chronic infection and lead to suboptimal immunity because of premature clonal contraction or T cell exhaustion. These studies have implications beyond providing a better understanding of immunity to tuberculosis. Our data establish a novel paradigm for how cross-talk between the adaptive and innate immune system occurs. Therefore, the studies proposed below will address a potentially critical, but as yet underappreciated immunological pathway, that affects immunity to tuberculosis and possibility other pathogens as well. Our aims are: 7 Aim 1. How does Tim3/Gal9 activate MX, stimulate innate immunity, and lead to killing of intracellular Mtb? 7 Aim 2. Does IL-1 and its downstream mediators activate human MX to kill Mtb? 7 Aim 3. How does the Tim3/Gal9 interaction modulate immunity to tuberculosis in vivo?
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
The role of CD38 in immunity to tuberculosis
-
批准号:10727585
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2023
-
负责人:SAMUEL M BEHAR
-
依托单位:
Hypoxia, tuberculosis, and T cell dysfunction
-
批准号:10735553
-
项目类别:
-
资助金额:$72.97万
-
财政年份:2023
-
负责人:SAMUEL M BEHAR
-
依托单位:
Granulysin and the antimicrobial activity of CD8T cells - development of a better model
-
批准号:10192536
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2021
-
负责人:SAMUEL M BEHAR
-
依托单位:
Granulysin and the antimicrobial activity of CD8T cells - development of a better model
-
批准号:10356169
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2021
-
负责人:SAMUEL M BEHAR
-
依托单位:
Overcoming Genetic Variation in Vaccination
-
批准号:10219089
-
项目类别:
-
资助金额:$42.52万
-
财政年份:2017
-
负责人:SAMUEL M BEHAR
-
依托单位:
Tuberculosis and T cell Recognition
-
批准号:9081934
-
项目类别:
-
资助金额:$73.55万
-
财政年份:2016
-
负责人:SAMUEL M BEHAR
-
依托单位:
Tuberculosis and T cell Recognition
-
批准号:9221970
-
项目类别:
-
资助金额:$69.83万
-
财政年份:2016
-
负责人:SAMUEL M BEHAR
-
依托单位:
Regulation of CD8+ T cell immunity to tuberculosis (pending title)
-
批准号:8550320
-
项目类别:
-
资助金额:$60.56万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Regulation of CD8+ T cell immunity to tuberculosis (pending title)
-
批准号:8884534
-
项目类别:
-
资助金额:$64.78万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Apoptosis and efferocytosis: regulators of immunity to tuberculosis
-
批准号:8993894
-
项目类别:
-
资助金额:$49.62万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Apoptosis and efferocytosis: regulators of immunity to tuberculosis
-
批准号:8791297
-
项目类别:
-
资助金额:$49.62万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Apoptosis and efferocytosis: regulators of immunity to tuberculosis
-
批准号:8605506
-
项目类别:
-
资助金额:$49.54万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Tim3 and Mycobacterium tuberculosis
-
批准号:8629422
-
项目类别:
-
资助金额:$49.44万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
The effect of type I IFN and IL-12 signaling on T cell immunity to tuberculosis
-
批准号:8629409
-
项目类别:
-
资助金额:$20.81万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Regulation of CD8+ T cell immunity to tuberculosis
-
批准号:10397020
-
项目类别:
-
资助金额:$70.46万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Apoptosis and efferocytosis: regulators of immunity to tuberculosis
-
批准号:8629352
-
项目类别:
-
资助金额:$33.82万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Regulation of CD8+ T cell immunity to tuberculosis (pending title)
-
批准号:8711279
-
项目类别:
-
资助金额:$64.78万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Regulation of CD8+ T cell immunity to tuberculosis
-
批准号:9918239
-
项目类别:
-
资助金额:$70.46万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
The effect of type I IFN and IL-12 signaling on T cell immunity to tuberculosis
-
批准号:8331116
-
项目类别:
-
资助金额:$23.02万
-
财政年份:2012
-
负责人:SAMUEL M BEHAR
-
依托单位:
Apoptosis and efferocytosis: regulators of immunity to tuberculosis
-
批准号:8416345
-
项目类别:
-
资助金额:$9.89万
-
财政年份:2012
-
负责人:SAMUEL M BEHAR
-
依托单位:
海外基金